drugset / Trial / NCT02323659

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

NCT02323659

Phase 4 Terminated 100 enrolled Polish Lymphoma Research Group
RandomizedParallel-groupOpen-labelTreatment

Summary

Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.

Timeline

Start
2014-06-01
Primary completion
2018-03
Completion
2018-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methotrexate Small molecule 20 mg Oral
Comparator interferon alfa-2b Protein / enzyme biologic 3 iu

Indications